ClinicalTrials.gg
TerminatedNCT05564325Updated Apr 13, 2026

Real-time Deflectable Guidewire in Neuro-interventions Study

An interventional study of SmartGUIDE (deflectable guidewire) in Unruptured Cerebral Aneurysm, sponsored by Artiria Medical. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Artiria Medical · Not applicable, Interventional, and Other

How we know

Why this study was terminated
The study was prematurely terminated after the successful completion of the pilot phase and the EU CE marking was obtained, rendering the continuation no longer necessary. The study was not terminated for reasons related to participants' safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Intracranial Aneurysm with a site in Switzerland — 8 open to participants now, 9 under way, none of them phase 3. Intracranial Aneurysm · Switzerland.

Started
2023
with 1 other
No phase
4 of 21
none open now
Registered
19th of 21
by date
Lead sponsor
1 of 21
Artiria Medical

Among the 21 studies in Intracranial Aneurysm with a site in Switzerland, this one is one of 2 that started in 2023, is one of 4 with no phase, and was the 19th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

8 of the 21 studies in Intracranial Aneurysm with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Intracranial Aneurysm with a site in Switzerland, or all of them as a file.
02

Study summary

The aim of the study is to assess the safe and successful use of the SmartGUIDE guidewire in neuro interventions and to compare to standard of care guidewires on the market.

03

Conditions studied

  • Unruptured Cerebral Aneurysm

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years of age
  • signed by patient
  • Confirmed cerebral unruptured aneurysm treatable via transcatheter approach

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Known disorder of vascular fragility with propensity to vascular injury (e.g., Ehlers-Danlos syndrome)
  • Known prior vascular stenosis or dissection or injury to vessels intended to be catheterized during study procedures
  • Acute phase myocardial infarction or uncontrolled cardiac arrhythmia
  • Uncontrolled serum electrolyte imbalance
  • Bleeding disorder which limits the use of antiplatelet and/or anticoagulant therapy
  • Known to intravascular contrast material that cannot be adequately controlled with pre-medication
  • Known to Nickel
  • Subjects currently enrolled in another device or drug study that clinically interferes with the current study endpoints
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    SmartGUIDE (deflectable guidewire)

    Device: SmartGUIDE (deflectable guidewire)

Interventions

  • DeviceSmartGUIDE (deflectable guidewire)

    SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.

06

What researchers measure

Primary outcomes

  1. Performance

    Intra-procedural technical success defined as successful navigation of device to the vascular target vessel without need for shaping, removal or exchange.

    Time frame: During index procedure

Secondary outcomes

  1. Usability

    Usability data (pushability, trackability, navigatability, shape retention, support, and proximal access complexity) collected through questionnaire completed by the physician. Measured through a Likert scale from 1-5.

    Time frame: During index procedure

  2. Procedural times

    Procedural times (duration of tip reshaping, duration of access to target, duration of fluoroscopic exposition).

    Time frame: During index procedure

  3. Safety - intra- and postprocedural

    Adverse events, measured by the occurrence of adverse events

    Time frame: During index procedure and up to 48 hours post procedure

  4. Device Deficiencies

    Intraprocedural device deficiencies, measured by the occurrence of device deficiencies/malfunctions

    Time frame: During index procedure

07

Study locations

1 site
  • Geneva University Hospital - HUG
    Geneva, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Mar 2026, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 3, 2022
StartActual
Apr 19, 2023
Primary completionActual
Mar 10, 2026
CompletionActual
Mar 10, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05564325
Lead sponsor
Artiria Medical
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Apr 19, 2023
Primary completion
Mar 10, 2026
Completion
Mar 10, 2026
Last update
Apr 13, 2026

Study contacts

Paolo Machi, Professor
principal investigator · Geneva University Hospital - HUG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion